MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics

AI SummaryClose X

MindMaze Therapeutics is consolidating its global reimbursement strategy for next-generation neurotherapeutics, integrating U.S. Category III reimbursement for home-based digital neurorehabilitation, national evidence-generation programs in Switzerland via the CHF 11.2 million Innosuisse-backed SwissNeuroRehab consortium, and guideline-aligned engagement in the UK with NICE frameworks. This approach aims to enable scalable patient access and sustainable commercial growth by demonstrating real-world feasibility, utilization, and outcomes, supporting a service-based care model that aligns reimbursement with patient usage and clinical oversight, and building a foundation for long-term reimbursement durability across major healthcare systems.

Disclaimer*

UK 100

Latest directors dealings